Liver Cancer Drug Market, By Drug Class (VEGF Inhibitors, PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors (TKIs)), By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Liver Cancer Drug Market size was valued at USD 3,151.90 Million in 2023, expanding at a CAGR of 17.82% from 2024 to 2032.
The Liver Cancer Drug Market focuses on pharmaceutical treatments for hepatocellular carcinoma (HCC), the most common type of liver cancer, accounting for approximately 75% of all liver cancer cases. Rising incidences of liver cancer, attributed to factors like hepatitis infection and alcohol consumption, have heightened the demand for effective therapies. For instance, the World Health Organization estimates that liver cancer caused around 830,000 deaths globally in 2020. The advent of targeted therapies, such as sorafenib and lenvatinib, has transformed treatment protocols, offering new hope for patients. However, challenges persist, including the high cost of innovative treatments and limited access to care in low-resource settings, which can hinder market growth. Furthermore, the lack of early diagnostic tools often results in late-stage diagnosis, complicating treatment options. Nevertheless, opportunities abound in research for novel therapies, particularly immunotherapy and combination treatments, as well as initiatives aimed at increasing awareness and screening, which could lead to earlier diagnosis and better patient outcomes in the liver cancer landscape.
Liver Cancer Drug Market- Market Dynamics
Rising Incidences of Liver Cancer Drive Growth in the Liver Cancer Drug Market
The rising incidences of liver cancer are significantly driving growth in the Liver Cancer Drug Market, as reported by the World Health Organization, which indicates that liver cancer cases have increased by over 75% in the past two decades. This alarming trend is primarily attributed to rising rates of hepatitis B and C infections, excessive alcohol consumption, and obesity, with the American Cancer Society estimating that in 2023, approximately 43,000 new cases of liver cancer will be diagnosed in the U.S. alone. As awareness grows regarding the importance of early detection and treatment, pharmaceutical companies are responding by developing innovative therapies. For instance, recent advancements in targeted therapies, such as immune checkpoint inhibitors, have shown promise in improving survival rates for patients with advanced liver cancer. Additionally, organizations like the American Association for the Study of Liver Diseases are promoting research and clinical trials to enhance treatment options and better understand the disease, thereby addressing the urgent need for effective therapies in this rapidly evolving market.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LIVER CANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genentech, Inc. (Roche)
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Others
GLOBAL LIVER CANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
VEGF Inhibitors
PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors (TKIs)
Immune Checkpoint Inhibitors
GLOBAL LIVER CANCER DRUG MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
Chemotherapy
Targeted Therapy
Immunotherapy
Combination Therapy
GLOBAL LIVER CANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
Oral
Intravenous
GLOBAL LIVER CANCER DRUG MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Hospitals
Oncology Clinics
Research Institutes
GLOBAL LIVER CANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
o The U.S.
o Canada
Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Russia
o Netherlands
o Sweden
o Poland
o Rest of Europe
Asia Pacific
o India
o China
o South Korea
o Japan
o Australia
o Thailand
o Indonesia
o Philippines
o Rest of APAC
Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
The Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Liver Cancer Drug Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Liver Cancer Drug Market Snippet by Drug Class
2.1.2. Liver Cancer Drug Market Snippet by Therapy Type
2.1.3. Liver Cancer Drug Market Snippet by Route of Administration
2.1.4. Liver Cancer Drug Market Snippet by End-User
2.1.5. Liver Cancer Drug Market Snippet by Country
2.1.6. Liver Cancer Drug Market Snippet by Region
2.2. Competitive Insights
3. Liver Cancer Drug Key Market Trends
3.1. Liver Cancer Drug Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Liver Cancer Drug Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Liver Cancer Drug Market Opportunities
3.4. Liver Cancer Drug Market Future Trends
4. Liver Cancer Drug Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Liver Cancer Drug Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Liver Cancer Drug Market Landscape
6.1. Liver Cancer Drug Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Liver Cancer Drug Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
7.1.2. VEGF Inhibitors
7.1.3. PD-1/PD-L1 Inhibitors
7.1.4. Tyrosine Kinase Inhibitors (TKIs)
7.1.5. Immune Checkpoint Inhibitors
8. Liver Cancer Drug Market – By Therapy Type
8.1. Overview
8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
8.1.2. Chemotherapy
8.1.3. Targeted Therapy
8.1.4. Immunotherapy
8.1.5. Combination Therapy
9. Liver Cancer Drug Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
9.1.2. Oral
9.1.3. Intravenous
10. Liver Cancer Drug Market – By End-User
10.1. Overview
10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
10.1.2. Hospitals
10.1.3. Oncology Clinics
10.1.4. Research Institutes
11. Liver Cancer Drug Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Liver Cancer Drug Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Liver Cancer Drug Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.9. Italy
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.10. United Kingdom
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.11. France
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.12. Russia
11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.13. Netherlands
11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.15. Poland
11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.16. Rest of Europe
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Liver Cancer Drug Key Manufacturers in Asia Pacific
11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.8. India
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.9. China
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.13. Thailand
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.14. Indonesia
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America
11.5.1. Overview
11.5.2. Liver Cancer Drug Key Manufacturers in Latin America
11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Liver Cancer Drug Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Liver Cancer Drug Industry
12.1. Competitive Dashboard
12.2. Company Profiles
12.2.1. AbbVie Inc.
12.2.2. Amgen Inc.
12.2.3. AstraZeneca PLC
12.2.4. Bayer AG
12.2.5. Bristol-Myers Squibb Company
12.2.6. Eisai Co., Ltd.
12.2.7. Eli Lilly and Company
12.2.8. F. Hoffmann-La Roche AG
12.2.9. Genentech, Inc. (Roche)
12.2.10. Gilead Sciences, Inc.
12.2.11. GlaxoSmithKline plc
12.2.12. Merck & Co., Inc.
12.2.13. Novartis AG
12.2.14. Pfizer Inc.
12.2.15. Sanofi S.A.
12.2.16. Takeda Pharmaceutical Company Limited
12.2.17. Others
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
